The global market for RNA Interference (RNAi) was estimated at US$116.7 Billion in 2024 and is projected to reach US$206.7 Billion by 2030, growing at a CAGR of 10.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the RNA Interference (RNAi) market.
The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in 'knockdown' experiments, where protein expression is reduced to investigate function without altering the genome. RNAi`s ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.
RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi`s specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi`s application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.
Global RNA Interference (RNAi) Market - Key Trends and Drivers Summarized
RNA interference (RNAi) is a vital biological process where RNA molecules inhibit gene expression, a mechanism discovered due to its role in silencing genes by neutralizing targeted messenger RNA (mRNA) molecules. RNA, essential in the coding, decoding, regulation, and expression of genes, facilitates RNAi through two types of small RNA molecules: small interfering RNA (siRNA) and microRNA (miRNA), each about 22 nucleotides long. SiRNAs are engineered to specifically target and silence particular mRNAs, preventing protein production, and are processed from double-stranded RNA, which is cleaved and transported into the cytoplasm. Conversely, miRNAs, originating from single-stranded RNA that folds into hairpin structures, broadly regulate protein synthesis. This discovery, which brought Andrew Fire and Craig Mello the Nobel Prize in 2006, underscored RNAi as a natural defense against genomic parasites and a crucial regulator in protein synthesis.The RNAi mechanism operates through a complex pathway where siRNAs and miRNAs guide the RNA-induced silencing complex (RISC) to target mRNAs, blocking their translation and signaling their degradation. This process is pivotal for ensuring that mRNAs do not exceed their necessary lifespan in protein synthesis. The therapeutic implications of RNAi are significant, providing a precise tool in molecular biology to fine-tune gene expression for studying gene functions and validating drug targets. This method is particularly valuable in 'knockdown' experiments, where protein expression is reduced to investigate function without altering the genome. RNAi`s ability to selectively inhibit specific genes makes it a powerful candidate for managing diseases, offering new treatment avenues for conditions traditionally challenging with existing therapies by targeting malfunctioning proteins.
RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi`s specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi`s application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.
Scope of Study:
The report analyzes the RNA Interference (RNAi) market in terms of units by the following Segments, and Geographic Regions/Countries:- Segments: Therapeutics (Oncology, Ocular Disorders, Respiratory Disorders, Liver Diseases, Neuronal Disorders, Other Therapeutics); Application (Drug Discovery & Development, Therapeutics, Other Applications)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Drug Discovery & Development segment, which is expected to reach US$118.1 Billion by 2030 with a CAGR of a 16.3%. The Therapeutics segment is also set to grow at 3.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, estimated at $29.5 Billion in 2024, and China, forecasted to grow at an impressive 16.5% CAGR to reach $59.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global RNA Interference (RNAi) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global RNA Interference (RNAi) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global RNA Interference (RNAi) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Alnylam Pharmaceuticals, Inc., Benitec BioPharma, Ionis Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Qiagen, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 12 companies featured in this RNA Interference (RNAi) market report include:
- Alnylam Pharmaceuticals, Inc.
- Benitec BioPharma
- Ionis Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Qiagen, Inc.
- Quark Pharmaceuticals, Inc.
- Silence Therapeutics PLC
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
- Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
- Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
- Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
- Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
- Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
- Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
- Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals, Inc.
- Benitec BioPharma
- Ionis Pharmaceuticals, Inc.
- Ionis Pharmaceuticals, Inc.
- Qiagen, Inc.
- Quark Pharmaceuticals, Inc.
- Silence Therapeutics PLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 178 |
| Published | July 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 116.7 Billion |
| Forecasted Market Value ( USD | $ 206.7 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
